Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
Recruiting now · Phase 2
Conditions studied: Cytomegalovirus Infections, Primary Immune Deficiency Disorder
In brief
CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Key facts
- Study ID
- NCT03266640
- Run by
- New York Medical College
- People needed
- 20
- Starts
- 2018-11-01
- Expected to finish
- 2027-12-31
- Last updated by the study team
- 2025-08-08
Who can join
Age: 0 and older, up to 79. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Children's Hospital Los Angeles — Los Angeles, California, United States (enrolling)
- University of California San Francisco — San Francisco, California, United States (enrolling)
- Indiana University — Indianapolis, Indiana, United States (enrolling)
- Johns Hopkins — Baltimore, Maryland, United States (enrolling)
- Washington University — St Louis, Missouri, United States (enrolling)
- New York Medical College — Valhalla, New York, United States (enrolling)
- Nationwide Children's Hosptial — Columbus, Ohio, United States (enrolling)
- Children's Hospital of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)
- Medical College of Wisconsin/Children's Hospital of Wisconsin — Milwaukee, Wisconsin, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.